Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $85.1 million.

  • Foghorn Therapeutics' Total Current Liabilities rose 4973.95% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 4973.95%. This contributed to the annual value of $67.0 million for FY2024, which is 1463.65% up from last year.
  • Foghorn Therapeutics' Total Current Liabilities amounted to $85.1 million in Q3 2025, which was up 4973.95% from $77.8 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Total Current Liabilities ranged from a high of $85.1 million in Q3 2025 and a low of $16.3 million during Q1 2021
  • Over the past 5 years, Foghorn Therapeutics' median Total Current Liabilities value was $55.2 million (recorded in 2022), while the average stood at $52.2 million.
  • In the last 5 years, Foghorn Therapeutics' Total Current Liabilities surged by 19538.94% in 2022 and then plummeted by 1018.06% in 2024.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Total Current Liabilities stood at $48.7 million in 2021, then grew by 13.38% to $55.2 million in 2022, then grew by 5.85% to $58.4 million in 2023, then grew by 14.64% to $67.0 million in 2024, then grew by 27.02% to $85.1 million in 2025.
  • Its Total Current Liabilities was $85.1 million in Q3 2025, compared to $77.8 million in Q2 2025 and $71.3 million in Q1 2025.